SCHEMBL3017324

SCHEMBL3017324

Cc1ccc(C)c(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4)CC3)n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 6/20 0.57
SMN1; SMN2 Q16637 7/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 2/20 0.45
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
MAPT P10636 4/20 0.43
USP2 O75604 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HTT P42858 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NFKB1 P19838 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017165 0.94 AR (0.61) ARSMN1; SMN2L3MBTL1ALDH1A1NPC1
SCHEMBL3013940 0.90 AR (0.57) ARSMN1; SMN2ALDH1A1MAPK1NPC1
SCHEMBL3017933 0.90 AR (0.57) ARSMN1; SMN2ALDH1A1MAPK1NPC1
SCHEMBL3015505 0.90 AR (0.54) ARSMN1; SMN2L3MBTL1ALDH1A1MAPK1
SCHEMBL3006464 0.89 AR (0.56) ARSMN1; SMN2L3MBTL1ALDH1A1MAPK1
SCHEMBL3012134 0.89 AR (0.55) ARSMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL3006648 0.89 AR (0.55) ARSMN1; SMN2ALDH1A1MAPK1NPC1
SCHEMBL2998605 0.88 SMN1; SMN2 (0.48) ARSMN1; SMN2L3MBTL1ALDH1A1MAPK1
SCHEMBL3015783 0.88 AR (0.53) ARSMN1; SMN2L3MBTL1ALDH1A1MAPK1
SCHEMBL3000174 0.88 AR (0.54) ARSMN1; SMN2ALDH1A1MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.